Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T84726
|
||||
Target Name |
Rho associated protein kinase
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Asthma [ICD10: J45] | ||||
Glaucoma [ICD9: 365; ICD10: H40-H42] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Spinal cord injury [ICD10: S14, S24, S34] | |||||
BioChemical Class |
Transferases (EC:2)
|
||||
EC Number |
EC 2.7.11.1
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Roclatan | Drug Info | Phase 3 | Glaucoma | [525325] |
AMA-76 | Drug Info | Phase 2 | Glaucoma | [524752] | |
AR-12286 | Drug Info | Phase 2 | Glaucoma | [524084] | |
Rhopressa | Drug Info | Phase 2 | Glaucoma | [533091] | |
Cethrin | Drug Info | Phase 1/2 | Spinal cord injury | [536648] | |
Y-39983 | Drug Info | Phase 1/2 | Glaucoma | [522584] | |
AT13148 | Drug Info | Phase 1 | Solid tumours | [523886] | |
Y-27632 | Drug Info | Terminated | Asthma | [540753], [546846] | |
References | |||||
Ref 522584 | ClinicalTrials.gov (NCT00846989) Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension. U.S. National Institutes of Health. | ||||
Ref 523886 | ClinicalTrials.gov (NCT01585701) Phase I Study of AT13148, a Novel AGC Kinase Inhibitor. U.S. National Institutes of Health. | ||||
Ref 524084 | ClinicalTrials.gov (NCT01699464) A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months. U.S. National Institutes of Health. | ||||
Ref 524752 | ClinicalTrials.gov (NCT02136940) Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension. U.S. National Institutes of Health. | ||||
Ref 525325 | ClinicalTrials.gov (NCT02558400) Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension. | ||||
Ref 533091 | Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4. | ||||
Ref 531381 | A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96. | ||||
Ref 531577 | Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1. | ||||
Ref 532649 | AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.